Division of Pediatric Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Pediatr Nephrol. 2024 Jan;39(1):141-148. doi: 10.1007/s00467-023-06074-x. Epub 2023 Jul 17.
Primary hyperoxaluria type 1 (PH1) is a rare, severe genetic disease causing increased hepatic oxalate production resulting in urinary stone disease, nephrocalcinosis, and often progressive chronic kidney disease. Little is known about the natural history of urine and plasma oxalate values over time in children with PH1.
For this retrospective observational study, we analyzed data from genetically confirmed PH1 patients enrolled in the Rare Kidney Stone Consortium PH Registry between 2003 and 2018 who had at least 2 measurements before age 18 years of urine oxalate-to-creatinine ratio (Uox:cr), 24-h urine oxalate excretion normalized to body surface area (24-h Uox), or plasma oxalate concentration (Pox). We compared values among 3 groups: homozygous G170R, heterozygous G170R, and non-G170R AGXT variants both before and after initiating pyridoxine (B6).
Of 403 patients with PH1 in the registry, 83 met the inclusion criteria. Uox:cr decreased rapidly over the first 5 years of life. Both before and after B6 initiation, patients with non-G170R had the highest Uox:cr, 24-h Uox, and Pox. Patients with heterozygous G170R had similar Uox:cr to homozygous G170R prior to B6. Patients with homozygous G170R had the lowest 24-h Uox and Uox:cr after B6. Urinary oxalate excretion and Pox tend to decrease over time during childhood. eGFR over time was not different among groups.
Children with PH1 under 5 years old have relatively higher urinary oxalate excretion which may put them at greater risk for nephrocalcinosis and kidney failure than older PH1 patients. Those with homozygous G170R variants may have milder disease. A higher resolution version of the Graphical abstract is available as Supplementary information.
1 型原发性高草酸尿症(PH1)是一种罕见的严重遗传性疾病,导致肝脏草酸生成增加,从而导致尿路结石病、肾钙质沉着症,并且常进展为慢性肾脏病。对于 PH1 患儿,尿液和血浆草酸值随时间的变化的自然史知之甚少。
本研究为回顾性观察研究,分析了 2003 年至 2018 年间纳入罕见肾结石联盟 PH 登记处的基因确诊 PH1 患者的数据,这些患者在 18 岁之前至少有 2 次尿草酸与肌酐比值(Uox:cr)、24 小时尿草酸排泄与体表面积比值(24-h Uox)或血浆草酸浓度(Pox)的测量值。我们比较了 3 组患者的结果:纯合子 G170R、杂合子 G170R 和非 G170R AGXT 变异体,比较了在开始使用吡哆醇(B6)前后的结果。
登记处共有 403 例 PH1 患者,其中 83 例符合纳入标准。Uox:cr 在生命的前 5 年内迅速下降。在开始 B6 前后,非 G170R 患者的 Uox:cr、24-h Uox 和 Pox 均最高。在开始 B6 之前,杂合子 G170R 的 Uox:cr 与纯合子 G170R 相似。纯合子 G170R 在开始 B6 后 24-h Uox 和 Uox:cr 最低。儿童期期间,尿液草酸排泄和 Pox 随时间推移呈下降趋势。各组间的 eGFR 随时间无差异。
5 岁以下的 PH1 患儿尿液草酸排泄较高,与年龄较大的 PH1 患者相比,他们可能面临更高的肾钙质沉着症和肾衰竭风险。那些携带纯合子 G170R 变异体的患者可能疾病较轻。可在补充材料中获取图文摘要的高分辨率版本。